Celsion will begin Phase II trial of ThermoDox later this year

03/1/2010 | American City Business Journals

A Phase II trial of liver cancer treatment ThermoDox will kick off worldwide in the second half of this year, biotech firm Celsion announced. New York's Albert Einstein College of Medicine will participate in the randomized study, which will focus on the efficacy of ThermoDox in treating liver cancer and tumors when combined with radiofrequency therapy.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ